rubitecan

rubitecan

Oncology A topoisomerase inhibitor in trials for treating ovarian, colorectal, gastric, liver, lung, breast, pancreas, prostate, cervical, head & neck CA, myelodysplastic syndrome, CML, melanoma, glioma, sarcoma
References in periodicals archive ?
The first topoisomerase inhibitors are given by injection, but a new one -- Orathecin, formerly named Rubitecan -- now waiting for FDA approval for pancreatic cancer, is taken orally.
2-methoxyestradiol, AEE-788, aglycon protopanaxadiol, aplidine, ARQ-501, arsenic trioxide, BMS-387032, canertinib dihydrochloride, canfosfamide hydrochloride, combretastatin A-4 prodrug, idronoxil, indisulam, INGN-201, mapatumumab, motexafin gadolinium, oblimersen sodium, OGX-011, patupilone, PXD-101, rubitecan, tipifarnib, trabectedin etc.
4-1BBL, 506U78, Actimmune, Ad-IFNg, AlloMune, AMD-3100, Aplidin, ASIbcl, Atragen, Avastin, BCX1777, B-E8, Beta LT, Bexxar, Caelyx, Calsed, Campath, Clofarabine, CMC-544, CpG-7909, Depocyte, Edodekin Alpha, Elsamitrucin, FAVID, Fludara, FR-901228, Ganite, GEMZAR, GENASENSE, GRN163, GTI-2040, GTOP-99, hA20, HMR1275, HSPPC-96, Hu1D10, hum291, HuMax, IDEC-114, IDEC-152, IDIOVAX, Intron A, INX-3280, ISF-154, KiroMAb, LY317615, Lymphocide, Lymphorad131, MDX-060, MGV, Midostaurin, MT103, NIPENT, NOVATRONE, Oncolym, OncoTCS, Ontak, Orathecin Rubitecan, Parlodel, PEGIntron, Porleukin, Pretarget Lymphoma, PRO64553, Product R, Prothecan, Remitogen, Rituxan, SGN-30, SGN-35, T-900607, TH9402, Thalidomid, Trap, TRISENOX, UCN-01, VAXID, VB2-011, VEGF Trap, VELCADE, Zevalin
SuperGen is currently marketing Nipent(R) (for the treatment of cancer patients with lymphocytic malignancies) and is currently in Phase III clinical trials with its proprietary drug rubitecan for the treatment of pancreatic cancer.
Rubitecan, SuperGen's proprietary compound for the treatment of a variety of solid and hematological malignancies, is currently in Phase III clinical trials for pancreatic cancer in over 120 cancer centers across the United States.
Rubitecan is currently in Phase III clinical trials for pancreatic cancer in over 120 cancer centers across the United States.
Such statements, including those regarding the clinical development of Rubitecan (RFS 2000), involve certain risks and uncertainties associated with an emerging pharmaceutical company actively involved in clinical trials.